Covered recipient · General Payments record
CYNTHIA NAST
Allopathic & Osteopathic Physicians Pathology Anatomic Pathology & Clinical Pathology
General Payments · PY2020–2024
$21,066.96
- Reported across 21 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $3,185.00 | 2 |
| Travel and Lodging | $920.47 | 3 |
| Food and Beverage | $396.37 | 6 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| BioCryst Pharmaceuticals, Inc. | $3,185.00 | 2 |
| GlaxoSmithKline, LLC. | $1,107.31 | 7 |
| Retrophin, Inc. | $105.94 | 1 |
| Amgen Inc. | $103.59 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (11)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | $103.59 | 10/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117337002 | CMS |
| BioCryst Pharmaceuticals, Inc. | $637.00 | 01/05/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1117471424 | CMS |
| BioCryst Pharmaceuticals, Inc. | $2,548.00 | 01/05/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1117474210 | CMS |
| GlaxoSmithKline, LLC. | $31.02 | 11/15/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1116285022 | CMS |
| GlaxoSmithKline, LLC. | $616.99 | 11/15/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1116291008 | CMS |
| GlaxoSmithKline, LLC. | $272.46 | 12/06/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1116644570 | CMS |
| GlaxoSmithKline, LLC. | $55.65 | 12/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115755903 | CMS |
| GlaxoSmithKline, LLC. | $46.38 | 12/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116259409 | CMS |
| GlaxoSmithKline, LLC. | $64.93 | 12/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116691483 | CMS |
| GlaxoSmithKline, LLC. | $19.88 | 12/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116718665 | CMS |
| Travere Therapeutics, Inc. | $105.94 | 10/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1149894659 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2020, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.